| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We are trying to find biomarkers that can help to diagnose the primary unknown metastatic carcinomas. In this process, we identified that PPP2R1A mutations frequently occurred in GIST and that patients with GIST having this mutation showed adverse clinical outcome. We also showed that the type of NAB2-STAT6 fusion, which is specifically observed in solitary fibrous tumor (SFT), affects patients' prognosis. Furthermore, TERT promoter mutation and TP53 mutation were associated with the acquisition of the aggressive behavior, especially in the process of dedifferentiation of this tumor. We have previously shown that lung adenocarcinoma was the most common carcinoma among the primary unknown metastatic bone tumors. We also showed that galectin-4 could be a diagnostic marker for the metastatic lung adenocarcinoma, because the metastatic lung adenocarcinomas tend to lose TTF-1 expression, a marker of lung adenocarcinoma, while keeping the galectin-4 expression at the metastatic sites.
|
